GastroenterologyNews.net

Gastroenterology Xagena

Researchers have found early evidence that a common but harmless virus could be behind the celiac disease, by causing the immune system to turn against gluten. Up until now, research has mainly foc ...


Vedolizumab ( Entyvio ) is a gut-selective antibody to alpha4beta7 integrin for the treatment of ulcerative colitis and Crohn's disease. An integrated summary of the safety of Vedolizumab was reported ...


Data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of investigational oral GED-0301 ( Mongersen ) 160 mg on both endoscopic response and clinical remi ...


Interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral Mongersen ( GED-0301 ) on both endoscopic and clinical outcomes in patients ...


Clostridium difficile infection ( CDI ) is the leading cause of antibiotic-associated diarrhea. Clostridium difficile infection has increased in incidence and severity over the past decade, and is a g ...


Recurrent Clostridium difficile infection ( rCDI ) contributes to a significant burden of disease in patients with inflammatory bowel disease ( IBD ). In the RECIDIVISM study, researchers have sough ...


Proton pump inhibitors ( PPIs ) have been associated with adverse clinical outcomes amongst Clopidogrel ( Plavix ) users after an acute coronary syndrome. Recent pre-clinical results suggest that th ...


Favourable efficacy and safety profiles for Simeprevir ( Olysio ) in combination with Pegylated interferon alpha ( PEG-IFN alpha ) and Ribavirin ( triple therapy ) have been shown in clinical trials. ...


Infliximab ( Remicade ) has been shown to have beneficial effects on bone metabolism in patients with Crohn's disease ( CD ) although as yet the exact mechanisms have not been fully elucidated. A s ...


Endoscopic healing and clinical remission are important parameters to evaluate therapeutic efficacy in Crohn's disease. The aim of a study was to investigate the clinical effectiveness of Adalimumab ...


Data about the effectiveness of biologics, including anti-tumor necrosis factor ( anti-TNF ) therapy and anti-integrin strategies, in antibiotic refractory pouchitis or Crohn's disease-associated pouc ...


The objective of the present study was to evaluate the effectiveness and safety of Adalimumab ( Humira ) in children with Crohn disease ( CD ) who experienced Infliximab ( Remicade ) failure at the po ...


TNF inhibitors are effective in the treatment of ulcerative colitis. Adalimumab ( Humira ), a fully human TNF inhibitor, is increasingly used both as primary anti-TNF agent and in patients switching f ...


The efficacy of Adalimumab ( Humira ) in children with moderately to severely active Crohn’s disease enrolled in the IMAgINE 1 trial has been reported up to week ( wk ) 52. Long-term efficacy of Adali ...


The FDA ( Food and Drug Administration ) has approved Ramucirumab ( Cyramza ) in combination with Paclitaxel as a treatment for people with advanced or metastatic gastric or gastroesophageal junction ...